I have conducted an honest review of all Hoodia weight loss products which claim to give almost miraculous weight loss results for dieters worldwide. Read my Hoodia weight loss review now at
http://www.hoodia-weight-loss-review.com
Archive for Drug
Feb
01
This is what they don’t want the American people to know….
THE BAYH DOYLE ACT THE FIRST STEP TOWARDS COMMERCIALIZATION
This Act that Reagan introduced was intended to encourage the spreading of pharmaceutical education so that universities and the odd small business could patent the scientific discoveries from pharmaceutical research.
So, the public would pay for research that would ultimately serve the public’s health interest, in an industry that instantly became private. Our money then would now go to these big pharmaceutical companies instead of to improving the health of the American people.
The Bayh Doyle Act then has resulted in making the pharmaceuticals industry a $200 billion dollar industry every year. These are now the richest companies in the world.
And this has effectively changed the manner in which pharmaceutical education is disseminated. Now clinical trials are more biased than ever before, non-reporting of actual results is not happening, and the education behind real time data is being obscured and muddied. This is really happening people!
WHERE ARE YOUR DRUG DOLLARS GOING?
But wait, there is more. The government is behind all of it. In fact, the pharmaceutical industry is the largest lobbying body in Washington as we speak.
In 2002, the pharmaceutical industry employed almost 700 lobbyists, 26 of whom were former Congressmen, to lobby the government for higher costs in Medicare and more profits for the pharmaceutical industry.
That effort alone cost the taxpayers $91 million dollars alone, not to mention the challenges that the increased costs of Medicare incurred on the average American.
The corruption and scandal that lies behind the doors of the pharmaceutical industry is the education this country really needs, not the propaganda that we are paying for them to spit out.
I like to keep people informed of things like this, because the naysayers in this section work for and are paid by these same companies that try to keep us stupid. Their big money profits depend on keeping you and I in the dark.
We are taking back AMERICA! and not gonna take it anymore! You can believe that!
Hey Round 2, Little do you know that the pharmaceutical companies big money also finds it’s place in the lawyers pockets also. People need to open their eyes because I can see by comments like this that people just don’t KNOW!
Jan
30
Do you have to be at least 18 to do the clinical drug trials for cash?
Posted by: | CommentsThat’s basically it, you would think i don’t have to be, but I can not find a place where I don’t have to be.
If you can find a site or something please tell me
Dec
31
SUWON, SOUTH KOREA–(Marketwire – November 23, 2009) – AmKor (AmKor Pharma, Inc.) and Hengdian Group (Hengdian Group Ltd) today announced the signing of licensing agreement for further development and commercialization of Neu2000 in China.
Under the agreement terms, Hengdian Group will pay RMB 5 million Yuan as a research fund for the study of acute myocardial infarction (AMI) and burns immediately after signing and additional RMB 5 million Yuan as an upfront after completion of the phase II clinical trial for stroke, AMI or burns in China. Hengdian Group will provide 12 percent of the net sales as royalty to AmKor upon the commercial sale of the Neu2000 product in China. Moreover, Hengdian Group, as a pharmaceutical company specialized in active pharmaceutical ingredient (API) production for global clinical trials, is responsible for producing API and drug products of Neu2000 for multinational clinical trials through AmKor and Neurotech.
Neu2000 is a moderate, NR2B-selective N-methyl-d-aspartate (NMDA) receptor antagonist and potent antioxidant, which is developed as a dual cytoprotective drug for stroke, spinal cord injury (SCI), AMI and burns by Neurotech Pharmaceuticals Co., Ltd. (Neurotech) in South Korea. These therapeutic mechanisms have been among the most sought after activities in the pharmaceutical development of neuroprotectant and evaluated its efficacy over the past few decades through numerous studies of animal model such as ischemic stroke and SCI.
Neu2000 is an investigational stroke treatment with proven human safety through phase I clinical trial in Quintiles US. In the double-blinded, phase I clinical trial, Neu2000 showed excellent safety profiles up to 6 g per healthy young humans (80 subjects) and up to 4 g per normal elderly humans (15 subjects) without serious adverse events. Neu2000 did not show any Central Nervous System toxicities compared with other NMDA antagonists which have failed due to clinical toxicities. As dosing of only 125 to 1500 mg of Neu2000 per human was enough to exceed the therapeutic plasma concentrations showing maximal efficacy in animal models of stroke, SCI, and AMI, AmKor made a decision to move toward clinical proof-of-concept trial of Neu2000 for the target diseases.
Dr. BJ Gwag, President and CEO of AmKor and Neurotech, said, “We are pleased to establish a partnership with Hengdian Group with sincere trust and belief in the relationship and are going to plan phase II clinical trials of Neu2000 first in South Korea and China.”
AmKor, a Neurotech’s subsidiary, is a clinical-stage company focused on the development of drugs to treat the body’s response to injury. Its principle efforts are currently directed at advancing Neu2000 through phase II clinical trials in stroke, SCI, AMI and burns.
Neurotech is a biopharmaceutical venture company which discovers and develops new drugs for the treatment of neurological and inflammatory diseases.
The R&D of Neu2000 was supported partly by “National Research Laboratory grant,” “G7 grant” and “Functional Proteomics Project of the 21st Century Frontier Research Program” from the Ministry of Science and Technology in Korea. It was also supported by grants from “Brain Research Center” in Ajou University School of Medicine and from “Driving Force Project for the Next Generation” by Gyeonggi Provincial Government in Korea.
Hengdian Group is at the present one of the largest Chinese conglomerates, ranked 3rd in the “Top 10 National Private Enterprises,” with a total yearly turnover exceeding 16.7 billion RMB (over 2 billion USD). The headquarters is based in Hengdian, Zhejiang Province and the group has 3 public companies — electronics, pharmaceutical and chemical industry, film and entertainment — more than 60 sub-companies and about 200 manufacturing factories with over 40,000 employees.
Dec
21
Drug Regulatory Affairs – Careers & Prospects – Pharmaceutical Industry
Posted by: | Comments
What is Regulatory Affairs???? :-
Regulatory Affairs (RA) is an upcoming profession within the biomedical / health products sector. RA profession at its heart is all about Collecting, Analyzing and Communicating the Risks and Benefits of health care products to regulatory agencies and public all over the world.
In an organization their prime responsibilities involves preparation and presentation of registration documents to regulatory agencies and carry out all following discussion to obtain and maintain marketing authorization (MA) for the products concerned.
They need to keep a track on ever changing legislation in all countries where the companies is looking to market their product.
RA profession is broader than registration of products, they advise companies both strategically and technically at the highest level. Their role begins right from development of a product to making, marketing and post marketing. Their advice at all stages both in terms of legal and technical requirements and restrains help companies save a lot of time and money in developing the product and marketing the same.
They have a major contribution in company’s success both Commercially and Scientifically.
Careers in Regulatory Affairs:-
Pharma is a highly regulated industry the world over and professionals, who can manage regulatory affairs, are in high demand.
Selling drugs is not like selling anything else, when we sell drugs we need to be confident that
They do what they claim to do They have been through a tough testing process to get from the lab to the market The side effects are well documented
This is where regulatory affairs come in.
“Regulatory Affairs Professional is the key link to distributing your drugs to world region.”
The Indian Pharmaceutical industry is one of the fastest growing industry in India, with a CAGR of over 13 % in last 5 years and it is expected to grow at a higher rate in coming 10 years. It is valued at $ 8.0 billion approximately and ranks 4th in terms of volume and 13th in terms of value globally.
With such a high growth rate and rapid globalization there is a substantial need for highly trained professionals ready to perform the work required within this specialized industrial sector who will keep updates with regulatory law, policies and procedures for one or more product lines as well as maintain an understanding of the scientific and technical background of new products.
The increasing graph of the global companies’ setup in India demands the trained and skilled professional on a Handsome Salary, looking back for past few years rise in salary is multiplying.
There is a widening gap of rising demand and too few skilled human resource, this has seen a 50 % zoom on average in salaries for skilled manpower specifically in CRO sector alone. On an average there has been over 30% rises in salaries in Pharmaceutical Sector.
Research & Development activity in the Pharma sector is seeing a rapid growth and this growth is only poised to increase the need for skilled manpower and higher pay scale to retain the skilled.
What you will need to become a RA professional :-
A good background knowledge of the pharmaceuticals and medical environment A meticulous approach to work Attention to detail. Academic Qualification in Regulatory Affairs
You can expect to work in a multidisciplinary workplace where scientists and medics will come from very different backgrounds. Excellent written and verbal communication skills are a must as is the ability to work effectively under pressure.
Global Institute of Regulatory Affairs (GIRA)
GIRA has developed a Post Graduate Diploma (Sunday batches) and Advanced P.G. Diploma in RA (Full Time) which will surely help the professionals as the program address regulatory Affairs within each category of regulatory agencies of various country, Drugs and Medical devices.
This Program will be a complement to those who carrying Science, Pharmacy and Health related degrees, there are many rewarding career opportunities with regulatory affairs for individuals with a variety of backgrounds.
The courses has been developed, under the guidance of Industry and Government Experts, to provide broad regulatory foundations, exposure to the practical, real-world applications of the regulations, and an appreciation of the important roles that regulatory affairs professionals play in the bioscience industry.
Courses are taught by experienced regulatory professionals currently working in device, diagnostic, pharmaceutical and biologic sectors. Instructors bring the regulations to life and infuse their courses with relevant examples and hands-on exercises designed to prepare students for rewarding careers in regulatory affairs.
GIRA is a Division of “Perfect Pharmaceutical Consultants Pvt Ltd” – providing intelligent regulatory solutions since last 20 years
Please contact GIRA for “FREE Counseling & Course Prospectus”
To know more on RA and its Career visit White Paper section on
Global Institute of Regulatory Affairs
Sumit Gupta
Global Institute of Regulatory Affairs – www.regulatoryinstitute.com
Dec
15
Drug Regulatory Affairs – Careers & Prospects – Pharmaceutical Industry
Posted by: | Comments
What is Regulatory Affairs???? :-
Regulatory Affairs (RA) is an upcoming profession within the biomedical / health products sector. RA profession at its heart is all about Collecting, Analyzing and Communicating the Risks and Benefits of health care products to regulatory agencies and public all over the world.
In an organization their prime responsibilities involves preparation and presentation of registration documents to regulatory agencies and carry out all following discussion to obtain and maintain marketing authorization (MA) for the products concerned.
They need to keep a track on ever changing legislation in all countries where the companies is looking to market their product.
RA profession is broader than registration of products, they advise companies both strategically and technically at the highest level. Their role begins right from development of a product to making, marketing and post marketing. Their advice at all stages both in terms of legal and technical requirements and restrains help companies save a lot of time and money in developing the product and marketing the same.
They have a major contribution in company’s success both Commercially and Scientifically.
Careers in Regulatory Affairs:-
Pharma is a highly regulated industry the world over and professionals, who can manage regulatory affairs, are in high demand.
Selling drugs is not like selling anything else, when we sell drugs we need to be confident that
They do what they claim to do They have been through a tough testing process to get from the lab to the market The side effects are well documented
This is where regulatory affairs come in.
“Regulatory Affairs Professional is the key link to distributing your drugs to world region.”
The Indian Pharmaceutical industry is one of the fastest growing industry in India, with a CAGR of over 13 % in last 5 years and it is expected to grow at a higher rate in coming 10 years. It is valued at $ 8.0 billion approximately and ranks 4th in terms of volume and 13th in terms of value globally.
With such a high growth rate and rapid globalization there is a substantial need for highly trained professionals ready to perform the work required within this specialized industrial sector who will keep updates with regulatory law, policies and procedures for one or more product lines as well as maintain an understanding of the scientific and technical background of new products.
The increasing graph of the global companies’ setup in India demands the trained and skilled professional on a Handsome Salary, looking back for past few years rise in salary is multiplying.
There is a widening gap of rising demand and too few skilled human resource, this has seen a 50 % zoom on average in salaries for skilled manpower specifically in CRO sector alone. On an average there has been over 30% rises in salaries in Pharmaceutical Sector.
Research & Development activity in the Pharma sector is seeing a rapid growth and this growth is only poised to increase the need for skilled manpower and higher pay scale to retain the skilled.
What you will need to become a RA professional :-
A good background knowledge of the pharmaceuticals and medical environment A meticulous approach to work Attention to detail. Academic Qualification in Regulatory Affairs
You can expect to work in a multidisciplinary workplace where scientists and medics will come from very different backgrounds. Excellent written and verbal communication skills are a must as is the ability to work effectively under pressure.
Global Institute of Regulatory Affairs (GIRA)
GIRA has developed a Post Graduate Diploma (Sunday batches) and Advanced P.G. Diploma in RA (Full Time) which will surely help the professionals as the program address regulatory Affairs within each category of regulatory agencies of various country, Drugs and Medical devices.
This Program will be a complement to those who carrying Science, Pharmacy and Health related degrees, there are many rewarding career opportunities with regulatory affairs for individuals with a variety of backgrounds.
The courses has been developed, under the guidance of Industry and Government Experts, to provide broad regulatory foundations, exposure to the practical, real-world applications of the regulations, and an appreciation of the important roles that regulatory affairs professionals play in the bioscience industry.
Courses are taught by experienced regulatory professionals currently working in device, diagnostic, pharmaceutical and biologic sectors. Instructors bring the regulations to life and infuse their courses with relevant examples and hands-on exercises designed to prepare students for rewarding careers in regulatory affairs.
GIRA is a Division of “Perfect Pharmaceutical Consultants Pvt Ltd” – providing intelligent regulatory solutions since last 20 years
Please contact GIRA for “FREE Counseling & Course Prospectus”
To know more on RA and its Career visit White Paper section on
Global Institute of Regulatory Affairs
Sumit Gupta
Global Institute of Regulatory Affairs – www.regulatoryinstitute.com
Dec
15
SUWON, SOUTH KOREA–(Marketwire – November 23, 2009) – AmKor (AmKor Pharma, Inc.) and Hengdian Group (Hengdian Group Ltd) today announced the signing of licensing agreement for further development and commercialization of Neu2000 in China.
Under the agreement terms, Hengdian Group will pay RMB 5 million Yuan as a research fund for the study of acute myocardial infarction (AMI) and burns immediately after signing and additional RMB 5 million Yuan as an upfront after completion of the phase II clinical trial for stroke, AMI or burns in China. Hengdian Group will provide 12 percent of the net sales as royalty to AmKor upon the commercial sale of the Neu2000 product in China. Moreover, Hengdian Group, as a pharmaceutical company specialized in active pharmaceutical ingredient (API) production for global clinical trials, is responsible for producing API and drug products of Neu2000 for multinational clinical trials through AmKor and Neurotech.
Neu2000 is a moderate, NR2B-selective N-methyl-d-aspartate (NMDA) receptor antagonist and potent antioxidant, which is developed as a dual cytoprotective drug for stroke, spinal cord injury (SCI), AMI and burns by Neurotech Pharmaceuticals Co., Ltd. (Neurotech) in South Korea. These therapeutic mechanisms have been among the most sought after activities in the pharmaceutical development of neuroprotectant and evaluated its efficacy over the past few decades through numerous studies of animal model such as ischemic stroke and SCI.
Neu2000 is an investigational stroke treatment with proven human safety through phase I clinical trial in Quintiles US. In the double-blinded, phase I clinical trial, Neu2000 showed excellent safety profiles up to 6 g per healthy young humans (80 subjects) and up to 4 g per normal elderly humans (15 subjects) without serious adverse events. Neu2000 did not show any Central Nervous System toxicities compared with other NMDA antagonists which have failed due to clinical toxicities. As dosing of only 125 to 1500 mg of Neu2000 per human was enough to exceed the therapeutic plasma concentrations showing maximal efficacy in animal models of stroke, SCI, and AMI, AmKor made a decision to move toward clinical proof-of-concept trial of Neu2000 for the target diseases.
Dr. BJ Gwag, President and CEO of AmKor and Neurotech, said, “We are pleased to establish a partnership with Hengdian Group with sincere trust and belief in the relationship and are going to plan phase II clinical trials of Neu2000 first in South Korea and China.”
AmKor, a Neurotech’s subsidiary, is a clinical-stage company focused on the development of drugs to treat the body’s response to injury. Its principle efforts are currently directed at advancing Neu2000 through phase II clinical trials in stroke, SCI, AMI and burns.
Neurotech is a biopharmaceutical venture company which discovers and develops new drugs for the treatment of neurological and inflammatory diseases.
The R&D of Neu2000 was supported partly by “National Research Laboratory grant,” “G7 grant” and “Functional Proteomics Project of the 21st Century Frontier Research Program” from the Ministry of Science and Technology in Korea. It was also supported by grants from “Brain Research Center” in Ajou University School of Medicine and from “Driving Force Project for the Next Generation” by Gyeonggi Provincial Government in Korea.
Hengdian Group is at the present one of the largest Chinese conglomerates, ranked 3rd in the “Top 10 National Private Enterprises,” with a total yearly turnover exceeding 16.7 billion RMB (over 2 billion USD). The headquarters is based in Hengdian, Zhejiang Province and the group has 3 public companies — electronics, pharmaceutical and chemical industry, film and entertainment — more than 60 sub-companies and about 200 manufacturing factories with over 40,000 employees.
Dec
14
Drug Regulatory Affairs – Careers & Prospects – Pharmaceutical Industry
Posted by: | Comments
What is Regulatory Affairs???? :-
Regulatory Affairs (RA) is an upcoming profession within the biomedical / health products sector. RA profession at its heart is all about Collecting, Analyzing and Communicating the Risks and Benefits of health care products to regulatory agencies and public all over the world.
In an organization their prime responsibilities involves preparation and presentation of registration documents to regulatory agencies and carry out all following discussion to obtain and maintain marketing authorization (MA) for the products concerned.
They need to keep a track on ever changing legislation in all countries where the companies is looking to market their product.
RA profession is broader than registration of products, they advise companies both strategically and technically at the highest level. Their role begins right from development of a product to making, marketing and post marketing. Their advice at all stages both in terms of legal and technical requirements and restrains help companies save a lot of time and money in developing the product and marketing the same.
They have a major contribution in company’s success both Commercially and Scientifically.
Careers in Regulatory Affairs:-
Pharma is a highly regulated industry the world over and professionals, who can manage regulatory affairs, are in high demand.
Selling drugs is not like selling anything else, when we sell drugs we need to be confident that
They do what they claim to do They have been through a tough testing process to get from the lab to the market The side effects are well documented
This is where regulatory affairs come in.
“Regulatory Affairs Professional is the key link to distributing your drugs to world region.”
The Indian Pharmaceutical industry is one of the fastest growing industry in India, with a CAGR of over 13 % in last 5 years and it is expected to grow at a higher rate in coming 10 years. It is valued at $ 8.0 billion approximately and ranks 4th in terms of volume and 13th in terms of value globally.
With such a high growth rate and rapid globalization there is a substantial need for highly trained professionals ready to perform the work required within this specialized industrial sector who will keep updates with regulatory law, policies and procedures for one or more product lines as well as maintain an understanding of the scientific and technical background of new products.
The increasing graph of the global companies’ setup in India demands the trained and skilled professional on a Handsome Salary, looking back for past few years rise in salary is multiplying.
There is a widening gap of rising demand and too few skilled human resource, this has seen a 50 % zoom on average in salaries for skilled manpower specifically in CRO sector alone. On an average there has been over 30% rises in salaries in Pharmaceutical Sector.
Research & Development activity in the Pharma sector is seeing a rapid growth and this growth is only poised to increase the need for skilled manpower and higher pay scale to retain the skilled.
What you will need to become a RA professional :-
A good background knowledge of the pharmaceuticals and medical environment A meticulous approach to work Attention to detail. Academic Qualification in Regulatory Affairs
You can expect to work in a multidisciplinary workplace where scientists and medics will come from very different backgrounds. Excellent written and verbal communication skills are a must as is the ability to work effectively under pressure.
Global Institute of Regulatory Affairs (GIRA)
GIRA has developed a Post Graduate Diploma (Sunday batches) and Advanced P.G. Diploma in RA (Full Time) which will surely help the professionals as the program address regulatory Affairs within each category of regulatory agencies of various country, Drugs and Medical devices.
This Program will be a complement to those who carrying Science, Pharmacy and Health related degrees, there are many rewarding career opportunities with regulatory affairs for individuals with a variety of backgrounds.
The courses has been developed, under the guidance of Industry and Government Experts, to provide broad regulatory foundations, exposure to the practical, real-world applications of the regulations, and an appreciation of the important roles that regulatory affairs professionals play in the bioscience industry.
Courses are taught by experienced regulatory professionals currently working in device, diagnostic, pharmaceutical and biologic sectors. Instructors bring the regulations to life and infuse their courses with relevant examples and hands-on exercises designed to prepare students for rewarding careers in regulatory affairs.
GIRA is a Division of “Perfect Pharmaceutical Consultants Pvt Ltd” – providing intelligent regulatory solutions since last 20 years
Please contact GIRA for “FREE Counseling & Course Prospectus”
To know more on RA and its Career visit White Paper section on
Global Institute of Regulatory Affairs
Sumit Gupta
Global Institute of Regulatory Affairs – www.regulatoryinstitute.com
Dec
14
Is Avodart A Dual Purpose Drug?
Posted by: | CommentsDutasteride, which is commonly marketed under the brand name Avodart, belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). The drug was approved by the FDA for the treatment of prostate enlargement in men in 2002.
Avodart has not been approved for the treatment of hair loss, although physicians can use an approved medication in ways other than that it was specifically approved for. That said, the use of dutasteride certainly requires doctor supervision. Avodart is used mostly for men who have an enlarged prostate.
If your prostate is smaller, it will put less pressure on your urethra. AVODART has been shown to improve symptoms after 3 to 6 months, with continued improvement extending to 2 years, and this improvement can be maintained up to 4 years. By shrinking the prostate, it stops the symptoms associated with prostate enlargement from getting worse.
Like finasteride (the active ingredient in Propecia), dutasteride blocks the enzyme 5 alpha-reductase that converts testosterone to DHT (DHT causes hair loss). Unlike finasteride, which only inhibits the Type I form of the enzyme, dutasteride inhibits both the Type I and Type II forms. This combined effect lowers circulating DHT more with dutasteride than with finasteride, but also increases the incidence of side effects.
The Type II form of the enzyme (blocked by finasteride) is found predominantly in the hair follicle. The Type I form of the enzyme has been found in the scalp and sebaceous glands, but its exact role in hair growth has not been determined. It is felt that the ability of dutasteride to lower serum levels of DHT is what makes it a more potent medication in hair loss.
When considering the safety of dutasteride, one should consider several facts. It acts on other parts of the body besides the hair follicle. Unlike finasteride, where families that had a deficiency of the Type II 5-alpha reductase enzyme were followed for years without any adverse effects, there is no natural biologic model to show the safety of dutasteride.
Avodart has been approved for prostate enlargement in an older male population. It is not approved for hair loss and, in fact, the clinical trials for hair loss were discontinued, so there is no safety data for its use in younger patients. There is a greater incidence of sexual side effects with dutasteride compared to finasteride.
I hope you have found this information helpful. In any case, you should consult your physician before using Avodart. It may or may not be appropriate, depending on your medical situation, to use the drug to treat hair loss. Be sure to disclose to your physician any other drugs you might be taking before requesting a prescription for Avodart.
Jim Pretin is the owner of http://www.forms4free.com, a service that helps programmers make an HTML form
Dec
13
Avodart Is A Dual Purpose Drug
Posted by: | CommentsDutasteride, which is commonly marketed under the brand name Avodart, belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). The drug was approved by the FDA for the treatment of prostate enlargement in men in 2002.
Avodart has not been approved for the treatment of hair loss, although physicians can use an approved medication in ways other than that it was specifically approved for. That said, the use of dutasteride certainly requires doctor supervision. Avodart is used mostly for men who have an enlarged prostate.
If your prostate is smaller, it will put less pressure on your urethra. AVODART has been shown to improve symptoms after 3 to 6 months, with continued improvement extending to 2 years, and this improvement can be maintained up to 4 years. By shrinking the prostate, it stops the symptoms associated with prostate enlargement from getting worse.
Like finasteride (the active ingredient in Propecia), dutasteride blocks the enzyme 5 alpha-reductase that converts testosterone to DHT (DHT causes hair loss). Unlike finasteride, which only inhibits the Type I form of the enzyme, dutasteride inhibits both the Type I and Type II forms. This combined effect lowers circulating DHT more with dutasteride than with finasteride, but also increases the incidence of side effects.
The Type II form of the enzyme (blocked by finasteride) is found predominantly in the hair follicle. The Type I form of the enzyme has been found in the scalp and sebaceous glands, but its exact role in hair growth has not been determined. It is felt that the ability of dutasteride to lower serum levels of DHT is what makes it a more potent medication in hair loss.
When considering the safety of dutasteride, one should consider several facts. It acts on other parts of the body besides the hair follicle. Unlike finasteride, where families that had a deficiency of the Type II 5-alpha reductase enzyme were followed for years without any adverse effects, there is no natural biologic model to show the safety of dutasteride.
Avodart has been approved for prostate enlargement in an older male population. It is not approved for hair loss and, in fact, the clinical trials for hair loss were discontinued, so there is no safety data for its use in younger patients. There is a greater incidence of sexual side effects with dutasteride compared to finasteride.
I hope you have found this information helpful. In any case, you should consult your physician before using Avodart. It may or may not be appropriate, depending on your medical situation, to use the drug to treat hair loss. Be sure to disclose to your physician any other drugs you might be taking before requesting a prescription for Avodart.
Jim Pretin is the owner of http://www.forms4free.com, a service that helps programmers make an HTML form